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Abstract
Purpose VitaminAmetabolites, such as all-trans-retinoic acid
(RA) that act through the nuclear receptor; retinoic acid re-
ceptor (RAR), have been shown to polarise T cells towards
Th2, and to be important in resistance to helminth infections.
Co-incidentally, people harbouring intestinal parasites are of-
ten supplemented with vitamin A, as both vitamin A deficien-
cy and parasite infections often occur in the same regions of
the globe. However, the impact of vitamin A supplementation
on gut inflammation caused by intestinal parasites is not yet
completely understood.
Methods Here, we use Trichuris muris , a helminth parasite
that buries into the large intestine of mice causing mucosal
inflammation, as a model of both human Trichuriasis and IBD,
treat with an RARα/β agonist (Am80) and quantify the ensu-
ing pathological changes in the gut.
Results Critically, we show, for the first time, that rather than
playing an anti-inflammatory role, Am80 actually exacerbates
helminth-driven inflammation, demonstrated by an increased
colonic crypt length and a significant CD4+ T cell infiltrate.
Further, we established that the Am80-driven crypt hyperpla-
sia and CD4+ T cell infiltrate were dependent on IL-6, as both
were absent in Am80-treated IL-6 knock-out mice.
Conclusions This study presents novel data showing a pro-
inflammatory role of RAR ligands in T. muris infection, and
implies an undesirable effect for the administration of vitamin
A during chronic helminth infection.
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RA All-trans -retinoic acid
RAR Retinoic acid receptor
RARE Retinoic acid response element
RXR Retinoid X receptor
Treg Regulatory T cell
Introduction
Human Trichuriasis affects millions of people across the
globe, causing significant gut inflammation and morbidity.
The human nematode parasite Trichuris trichiura is modelled
in mice using the analogous parasite Trichuris muris . T.muris
buries into the colonic and caecal epithelium causing inflam-
mation which is characterised by morphological changes such
as intestinal crypt hyperplasia, as well as an infiltration of
inflammatory cells and the production of inflammatory medi-
ators [1–3]. Furthermore, the inflammation seen in response to
Trichuris muris infection, has demonstrated numerous simi-
larities to the genetic and pathological changes that occur
during human inflammatory bowel disease (IBD) [4].
Therefore, it is important to understand the mechanisms that
mediate the inflammatory processes during infection with this
intestinal parasite, not only from a parasitological point of
view and but also because of its relevance to other diseases.
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Resistance to T. muris is critically dependent on the ability
of the mouse to mount a Th2 response, characterised by the
secretion of cytokines such as IL-4, IL-5, IL-6, IL-9 and IL-13
[5] and is exemplified by acute infection of the BALB/c strain
of mouse. Conversely, susceptible strains of mouse, such as
AKR, make an inappropriate Th1 response, identified by the
production of IFN-γ [6] and develop chronic patent infections
[7]. Furthermore, manipulation of infection dose determines
whether an acute or chronic infection prevails in C57BL/6
mice [8]. Thus, high levels of infection of 100–200 eggs are
expelled, whilst low-level infections, establishing from fewer
than 60 eggs, persist. Low-level infection of C57BL/6 mice is
therefore a useful tool to create susceptibility to infection equiv-
alent to that seen in certain inbred strains of mouse such as
AKR, enabling chronic infection experiments to be conducted
in the multitude of transgenic mouse strains that exist on a
C57BL/6 background.
Vitamin A and its major metabolite all -trans -retinoic acid
(RA) have recently been shown to be key regulators of im-
mune responses. RA regulates gene expression by binding to
the nuclear hormone receptors; retinoic acid receptor (RAR)
and retinoic X receptor (RXR), each of which exist in three
isoforms; α, β, and γ [9]. RAR proteins are expressed ubiq-
uitously and their expression is up-regulated in the presence of
retinoic acid [10]. Upon complexing with retinoic acid, the
RARs heterodimerise with nuclear hormone receptors
(NHRs) of the RXR family. These heterodimers then interact
with retinoic acid response elements (RAREs) within the
promoters of retinoic acid responsive genes to modify tran-
scriptional rates of, for example, inflammatory mediators [9].
RA has profound effects on the immune system, including
influencing the development of T cell subsets. Ex vivo stim-
ulation of lymphocytes from vitamin A-deficient mice induces
IFN-γ production, and these cells produce less IL-4 and IL-5
[11]. Conversely, supplementation with RA boosts IL-4, -5
and -10 production, while reducing IFN-γ [12, 13]. RARα-
selective retinoids can also inhibit the progression of Th1-
associated immunological diseases such as delayed type hy-
persensitivity [14] and experimental arthritis [15]. Therefore,
RA favours Th2 immune responses, and has been shown to
enhance the differentiation of these cells [16]. Recent work on
RA has focussed on its role in regulatory T cell (Treg) induc-
tion. Studies have shown that RA is able to induce the con-
version of naïve FoxP3−CD4+ T cells into FoxP3+ Tregs in
both mice and humans in vitro [17], and that FoxP3 expres-
sion is increased following RA treatment in colitis [18].
The role of RA in the regulation of chronic inflammation is
largely unexplored, despite its ability to regulate gene tran-
scription through NHRs. Further, its role in the induction of
regulatory Tcells might imply that vitamin A supplementation
is well placed to reduce inflammatory responses. Indeed,
vitamin A supplementation has been shown to reduce re-
infection rates and increase faecal IL-4 protein in Ascaris
lumbricoides-infected children [19, 20]. Beneficial effects of
RXR (RAR’s heterodimeric partner) agonists have been re-
ported in chemical models of IBD, and correlate with reduced
TNF-α production [21], but the mechanisms have not been
fully described. Here, we supplement chronically infected
mice with an RARα/β agonist (Am80) and show that Am80
exacerbates helminth-driven inflammation, described by an
exaggerated crypt hyperplasia and an increased cellular infil-
trate. Furthermore, we provide evidence that the Am80-driven
increase in mucosal inflammation occurs via an IL-6-
dependent mechanism. Since vitamin A is widely used to
lower morbidity in children and adults who harbour chronic
parasitic infections [19], our findings are a critical addition to
the understanding of potential therapies for chronically-
infected individuals, as well as our knowledge of vitamin A-
mediated immune responses in the gut mucosa.
Methods
Animals, T. muris and Compounds
Male AKR mice of 6–8 weeks of age were purchased from
Harlan (UK). Breeding pairs of IL-6−/− mice [22] and their
wild-type controls (IL-6+/+), back-crossed onto a C57BL/6
background were bred by the Biological Services Facility
(BSF, University of Manchester, UK). All mice were housed
at the BSF (University of Manchester) in sterile conditions,
within individually-ventilated cages. This investigation was
carried out in accordance with the UK Scientific Procedures
(Animals) Act 1986.
All experiments used the Edinburgh (E) strain of T. muris ,
which was maintained as previously described [23]. T. muris
Excretory/Secretory (E/S) antigen was collected by incubating
adult worms in RPMI 1640 medium for 4 or 24 h. AKR mice
were infected with ~200 eggs, while WT C57BL/6 and IL-6
KOmice were infected with 40–60 eggs to establish a chronic
infection. Worm burden analysis was conducted as previously
described [24]. Mice were treated orally with vehicle or an
RARα/β agonist (Am80; 20 mg/kg (dose taken from [21]),
obtained from Hiroyuki Kagechika, Tokyo Medical and
Dental University, Tokyo, Japan) daily from day 21 to day
35 post-infection. Am80 was dissolved in 2 % DMSO, 40 %
PEG, 58 % water and 2 drops of Tween 20. Vehicle treatment
consisted of this mixture without the active compound.
Histology
Proximal colon tissue was fixed in neutral-buffered formalin
and embedded in paraffin wax. Sections of 5 μm thickness
were de-waxed with Citroclear and rehydrated through de-
creasing concentrations of ethanol. Haematoxylin and eosin
staining was used to study the gut morphology. ImageJ
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analysis software (National Institutes of Health) was used to
measure proximal colon crypt length. Twenty measurements
from each tissue section were taken randomly.
Immunohistochemistry
Tissue samples from the proximal colon were frozen in
Optimal Cutting Temperature (OCT) embedding medium
(R.A. Lamb, Eastbourne, U.K.) and cut into 5 μm sections
(Micron HM560 cryostat). CD4+ cells and FoxP3+ cells were
identified by immunohistochemistry. Briefly, tissue samples
were fixed in 4 % paraformaldehyde in PBS. Endogenous
peroxidase activity was quenched using glucose/azide solution
with glucose oxidase (Sigma). Samples were blocked with 7 %
rat serum followed by an avidin/biotin blocking step. Biotin-
conjugated rat anti-mouse CD4 (eBioscience) was used at 5 μg/
ml in PBS. Rat anti-mouse FoxP3 antibody (eBioscience) was
used at 2.5 μg/ml in PBS followed by goat anti-rat secondary
(Santa Cruz) at 1:400. The avidin-biotin complex (ABC Kit,
Vector Laboratories), 3,3′-diaminobenzidine (DAB Kit,
Vector Laboratories), and haematoxylin (haematoxylin QS,
Vector Laboratories) steps were then conducted. CD4+
cells and FoxP3+ cells were assessed by counting the num-
ber of positively-stained cells per 20 crypt units, in three
sections per mouse.
Cell Culture and Cytokine Analysis
MLNs were removed from mice at day 35 post-infection and
the cells were resuspended in medium (RPMI 1640,
Invitrogen) supplemented with 10 % FCS, 1 % L-glutamine
and 100U/ml penicillin/100μg/ml streptomycin (all from PAA
Laboratories, GmbH, UK) at a concentration of 5×106/ml.
Cell cultures were stimulated with 50 μg/ml of T. muris
excretory/secretory antigen at 37 °C. For the Tcell stimulation
assay, 1×106 MLN cells in 1 ml were added to a 48-well plate
pre-coated with anti-CD3 antibody (3μg/ml) (eBioscience).
Anti-CD28 antibody (BD Biosciences) was added at 5μl/well.
Cells were left alone or treated with either 100 nM Am80,
1μM Am80 or vehicle (0.4 % DMSO). Plates were then
incubated at 37 °C/5 % CO2 in 95 % humidity for 48 h.
Bone marrow-derived macrophages (BMDM) were isolated
from C57BL/6 wild-type mice by flushing femurs with
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen)
containing 10 % FCS, 1 % L-glutamine and 100U/ml
penicillin/100μg/ml streptomycin (all from PAA Laboratories,
GmbH, UK) (complete DMEM). Cells were washed and cul-
tured at 1×106/ml in complete DMEM containg 30 ng/ml M-
CSF (eBioscience) for 7–10 days, with the media being re-
placed after 4–5 days. Macrophage purity was assessed
by staining with 7AAD viability stain (eBioscience), anti-
CD11b-APC-Cy7, anti-F4/80-APC and anti-CD11c-PE-
Cy7 (eBiosciences) and aquirng on a LSR II flow cytometer
(BD Biosciences). In all cultures used, the percentage of
7AAD−CD11b+F480+ cells were found to be over 72 %.
The BMDMs (0.5×106) were adhered to 48 well plates for
48 h in the presence of complete DMEMmedia alone or with
T.muris E/S (50 ng/ml). Two differing concentrations of Am80
(1μM or 100 nM) were also added to the appropriate wells.
CMT93, a mouse rectal epithelial cell line was grown in com-
plete DMEM in 48 well plates. When confluent, cells were left
for 48 h in the presence of completeDMEMmedia alone orwith
T. muris E/S (50 ng/ml). Again Am80 (1μM or 100 nM) was
also added to the appropriate wells. All supernatants were stored
at −20 °C until analyzed for cytokine content. Supernatants were
assessed for IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17a, IFN-γ,
TNF-α and CCL2 using a customised cytometric bead array
(CBA) kit (BD Biosciences).
Statistical Analyses
Statisical analysis was performed using either the Student’s
unpaired t-test, or one way ANOVA (with Tukey’s multiple
comparison post-hoc test) as appropriate with the statistical
package GraphPad Prism (Version 3). A p value of less than
0.05 was considered significant.
Results
Activating RAR Increases Intestinal Inflammation During
Chronic T. muris Infection Through an IL-6 Dependent
Mechanism
Given previous work showing a beneficial effect for retinoic
acid and activation of RAR in gut inflammation [18, 25] we
hypothesised that supplementing with a synthetic analogue of
retinoic acid during worm persistence may reduce intestinal
inflammation. Am80 is widely used in vivo in the mouse as an
agonist of RAR [15, 26, 27]. However, a single preliminary
experiment delivering Am80 to high-dose infected susceptible
AKR mice (Fig S1A) from day 21 onwards, revealed signif-
icantly exacerbated gut pathology. Thus, comparing Am80-
treated chronically infected mice with vehicle controls re-
vealed a significant increase in crypt lengths (Fig S1B
and C) and exacerbated CD4+ T cell infiltrate into the colon
(Fig S1D and E) in the former. Furthermore, we identified
significantly elevated levels of the pro-inflammatory cytokine
IL-6 in both the MLN and the gut (Fig. S1F and G). To dissect
these observations further, we chose to use the low dose
C57BL/6 chronic infection model [8], and explored the role
of IL-6 in the Am80-driven pathology through the use of IL-6
KO mice on a C57BL/6 background. As both C57BL/6 and
IL-6 KO mice are resistant to a high-dose infection (Hurst
et al., unpublished observations), C57BL/6 mice (wild-
type:WT, IL-6+/+) and IL-6 KO (IL-6−/−) mice were infected
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with a low dose (60 T. muris eggs) infection and treated from
day 21 to day 35 post-infection with vehicle or an RARα/β
agonist (Am80), during the development of a persistent infec-
tion and chronic inflammation. A low dose infection allows
the development of adult worms in all mouse strains [8].
As expected, at day 35 p.i. all mice harboured a low-dose
chronic infection with a spread of patent adult worm burdens
which is not atypical of this type of infection (Fig. 1a). WT
mice displayed increased crypt lengths following treatment
with Am80 during T. muris infection (p <0.05 compared to
vehicle controls) (Fig. 2b and c). Interestingly, this crypt cell
hyperplasia was not observed in IL-6 KO mice treated with
Am80: indeed crypt lengths were significantly lower compared
to Am80-treated wild-type mice (p <0.05) (Fig. 1b and c).
Crypt lengths in vehicle-treated wild-type and vehicle-
treated IL-6 KO mice post-infection were similar, indicating
that the decrease in mucosal inflammation seen in Am80-
treated IL-6 KO mice does not simply reflect the absence of
the pro-inflammatory mediator IL-6. There was no effect of
Am80 in uninfected animals (Fig. 1b and c).
Previously, retinoic acid has been shown to boost T cell
proliferation through RAR [28], as well as their migration to
the gut via up-regulation of gut homing receptors [29].
Therefore, we quantified the CD4+ infiltrate during T. muris
infection of the proximal colon by immunohistochemical
staining in chronically infected wild-type and IL-6 KO mice.
In both wild-type and IL-6 KO mice, the numbers of CD4+ T
cells in the proximal colon increased post-infection (Fig. 1d
and e). Am80-treatment lead to a further increase in the
number of CD4+ T cells in the wild-type animals (p <0.01),
however, this did not occur in IL-6 KO mice (Fig 1d and e).
Indeed in IL-6 KO mice treated with Am80, the number of
CD4+ Tcells in the gut was significantly lower than in Am80-
treated wild-type mice (p <0.05) (Fig. 1d and e).
In order to further determine the identity of these CD4+ T
cells infiltrating the gut following Am80 treatment of T.
Fig. 1 Activation of the retinoic acid receptor (RAR) increases pathology
during T. muris infection but not in the absence of IL-6. a Wild-type or
IL-6 KO mice were infected with 60T. muris eggs to establish a chronic
infection and treated with either vehicle or Am80. At day 35 p.i. worm
burdens were determined. b Paraffin-embedded proximal colon sections
were stained with haemotoxylin and eosin (H&E) and crypt lengths
measured using Image J software. c Representative images of T.
muris-infected proximal colon sections stained with H&E. The arrows
demonstrate examples of the measurements which were taken. d
Immunohistochemical staining of CD4+ cells was conducted on proximal
colon sections from wild-type and IL-6 knock-out animals at day 35 p.i.
Quantitative analysis of immunohistochemistry was carried out by
counting the number of positively-stained CD4+ cells. e A representative
image of each infected treatment group is shown, where positively stained
cells are brown. Scale bars indicate 200 μm. Graphs show means+SEM
(n=5). Data are representative of two independent experiments. *p<0.05,
**p<0.01, ***p<0.001
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muris -infected mice, FoxP3+ regulatory T cells (Tregs) were
quantified in the proximal colon of WT and IL-6 KO mice.
The pooled results of two independent experiments suggest
that in WT mice, the numbers of FoxP3+ cells in the proximal
colon increased post-infection, however, there was no signif-
icant affect on FoxP3+ cell numbers with Am80 treatment of
WTmice (Fig. S2), suggesting that they do not account for the
additional CD4+ infiltrate driven by Am80 treatment of WT
mice. Furthermore, Am80 treatment of IL-6 KO mice signif-
icantly decreased the numbers of FoxP3+ cell numbers in the
gut compared to vehicle controls, which would not help to
explain the decreased inflammation observed in this group
(Fig. S2). Overall, these data suggest that the Am80-driven
CD4+ Tcell infiltrate seen during chronic T.muris infection is
dependent on the production of IL-6, but does not involve the
generation of Tregs.
Parasite-specific cytokine responses of MLN cells were
analysed in order to explore any correlations between eleva-
tions in pro-inflammatory or regulatory cytokines and the
exaggerated pathology seen with Am80 treatment. In wild-
type (WT) mice, Am80 treatment had no significant effect on
the levels of the pro-inflammatory cytokines IFN-γ, IL-17A
and TNF-α compared to vehicle controls (Fig. 2a). IL-10 and
the Th2 cytokines; IL-9 and IL-13, were raised in Am80-
treated infected mice compared to vehicle controls, although,
this failed to reach statistical significance (Fig. 2a). However,
a dramatic rise in IL-6 production was seen in MLNs from
Am80-treated infected mice compared to vehicle controls
(Fig. 2a), suggesting a role for IL-6 in Am80-driven patholo-
gy. No effects of Am80 were observed in naïve wild-type
mice (Fig. 2a).
In infected IL-6 KO mice, levels of IFN-γ, IL-17A, IL-10
and TNF-α were increased with Am80 treatment (p <0.05, p
<0.05, p <0.01 and p <0.01, respectively, compared to vehicle
controls) (Fig. 2a), although, importantly, levels were not
significantly different to those seen in WT mice treated with
Am80, suggesting that the Am80-driven increases are inde-
pendent of IL-6, unlike the pathological changes shown in
Fig. 1. Levels of IL-9 and IL-13 did not change significantly
(p >0.05) in IL-6 KO mice with Am80-treatment compared to
IL-6 KO vehicle controls. Although levels of IL-9 and IL-13
produced by MLNs from IL-6 KO mice treated with Am80
were reduced compared to MLNs from WT mice treated with
Am80, this difference was not statistically significant in both
independent experiments (Fig. 2a). Therefore, it is unlikely that
changes in these cytokines can help to explain the decreased
pathology observed in IL-6 KO mice treated with Am80
compared to WT mice. By definition, the Am80-driven
increase in IL-6 seen in WT mice was not observed in IL-6
KO mice (p <0.001), both validating the KO and supporting
Fig. 2 Am80 treatment of T. muris-infected mice increases the produc-
tion of IL-6. In the absence of IL-6, Am80 can still imprint gut homing on
MLN T cells. Wild-type or IL-6 KO mice were infected with a low-dose
of T. muris eggs to induce a chronic infection and treated with either
vehicle or Am80 between days 21 and 35p.i.. At day 35p.i. MLN cells
were isolated. a 5×106MLN cells were culturedwith T.muris Excretory/
Secretory (E/S) antigen at 50μg/ml for 48 h. Levels of IL-9, IL-13, IFN-γ,
TNF-α, IL-6, IL-10 and IL-17A were measured by CBA. Data are
representative of two independent experiments. b Flow cytometric anal-
ysis ofMLN cells. Graph shows the percentage of 7AAD−CD4+ cells that
are α4β7+. All graphs show means + SEM (n =4–8). *p <0.05, **p<
0.01, ***p <0.001, ns = no significance
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the role for IL-6 in Am80-driven pathology. No effects of
Am80 were observed in naïve IL-6 KO mice (Fig. 2a).
Am80 Imprints Gut Homing on T Cells, But This is Not IL-6
Dependent
To determine whether the CD4+ infiltrate seen with Am80-
treatment of T. muris-infected mice was due to enhanced gut
homing we isolated MLN cells from Am80-treated wild-type
and IL-6 KOmice and stained themwith antibodies forα4β7.
Flow cytometric analysis revealed an increase in the percent-
age ofα4β7-positive cells in the MLNs of both Am80-treated
wild-type and IL-6 KO mice (p <0.001 compared to vehicle
controls). This Am80-driven increase occurred in both
uninfected and infected mice (p <0.001 in wild-type mice
compared to vehicle controls) (Fig. 2b).
To determine whether the Am80-driven CD4+ infiltrate
observed in T. muris -infected mice was due to increases in
gut chemokines attracting T cells to the site of infection,
qPCRs were carried out on gut tissue from Am80-treated
wild-type and IL-6 KO mice infected with T. muris to day
35 p.i. The expression of the T cell chemokines CCL3, CCL5,
CXCL10, CXCL11, CCL20 and CCL28 was analysed. No
differences were observed at this time point that could account
for the Am80-driven CD4+ infiltrate (data not shown).
Overall, these results suggest that neither an increase in
CD4+ T cell gut homing nor enhanced chemotaxis underlie
the IL-6 dependent Am80-driven T cell infiltrate observed in
T. muris -infected mice.
Am80 Drives IL-6 Production from T Cells During T. muris
Infection
As the Am80-dependent increase in pathology was dependent
on IL-6, we went on to determine a possible cellular source of
the Am80-driven increase in IL-6 production during T. muris
infection. MLNs were taken from naïve and infected, wild-
type mice at day 21 p.i. and Tcells were stimulated using anti-
CD3 and anti-CD28 antibodies, and cultured with vehicle,
Am80 (1μM) or Am80 (100 nM) in vitro. T cells from
naïve, wild-type mice produced low levels of IL-6 and the
addition of Am80 at either concentration had no affect on IL-6
production (Fig. 3a). T cells from T. muris -infected mice
however, produced higher levels of IL-6 than naïve T cells
(Fig. 3a). Addition of Am80 (1μM) led to a significant
increase in IL-6 levels compared to both untreated cells
(p <0.05) and vehicle treated cells (p <0.001) (Fig. 3a).
Levels of IL-6 produced by T cells cultured with 100nM
Am80 were not significantly different from vehicle-treated
controls, indicating a dose-dependent effect (Fig. 3a).
Bone marrow-derived macrophages were cultured from
wild-type mice and stimulated in vitro with T. muris E/S
antigens. This increased the production of IL-6 by the
macrophages compared to media only controls (p <0.001)
(Fig. 3b), however, the addition of 1μM or 100 nM Am80
had no effect on the production of IL-6 and the levels were not
significantly altered from control values (Fig. 3b).
The mouse rectal epithelial cell line CMT93 was used to
investigate whether Am80 alters the production of IL-6 by
epithelial cells. Stimulating these cells with T. muris E/S
antigens increased the production of IL-6 by the epithelial
cells (p <0.01) (Fig. 3c) but no change in IL-6 production
was observed with the addition of 1μM or 100nM Am80
(Fig. 3c). These results suggest that T cells, but not macro-
phages or epithelial cells are able to respond to Am80 treat-
ment by increasing their production of IL-6, which may drive
pro-inflammatory response in the infected gut. Thus, T cells
may be the cellular source of the enhanced IL-6 production
observed following the treatment of T. muris -infected mice
with Am80.
Discussion
Vitamin A and its metabolites are biologically active agents
that canmediate immunological effects throughmodulation of
their nuclear hormone receptor RAR. Previously, retinoic acid
and activation of RAR have been shown to protect against
colitis, rheumatoid arthritis, and Trichinella spiralis infection
[15, 18, 30]. However, there are still many unanswered ques-
tions regarding the immunomodulatory effects of retinoic acid
in chronic mucosal inflammation and parasitic infections.
Here we present novel data showing a role for retinoic acid
in T. muris infection, which gives further insight into the
function of RAR in a biologically relevant model of gut
inflammation.
Many reports have shown that retinoic acid modulates the
Th1/Th2 balance in favour of Th2 responses [16, 31]. The
ability to expel T. muris is directly related to the development
of a Th2 immune response [32]. IL-9 and IL-13 are important
cytokines in immunity to intestinal nematodes [33–35].
However, in the current study, only a non-significant increase
in Th2 cytokines was observed in the MLNs of mice treated
with the RAR agonist Am80 and levels were not sufficient to
induce resistance to the low-dose infection as worms were still
present at day 35 p.i.. In contrast, previous studies have shown
that vitamin A deficiency in mice causes increased suscepti-
bility to acute infections with Nippostrongylus [36], increased
IFN-γ production and delayed expulsion following acute
Trichinella spiralis infection [30], as well as higher parasite
burdens and reduced Th2 cytokine responses in Schistosoma
mansoni -infected rats and mice [37, 38]. Although it is cur-
rently unclear why, there was a trend towards lower cytokine
levels in the vehicle-treated IL-6KO mice compared to WT
controls. These levels are amplified in the presence of Am80.
Furthermore, we have unpublished data showing that mice
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which lack the IL-6 receptor on Tcells (CD4-CreGP130flf/mice)
are still able tomakeTh1, Th2, Treg and Th17 derived cytokines
(Hurst & Else, unpublished findings). Thus, it is unlikely that T
cells are unable to respond to parasite antigen in the absence of
IL-6. Equally, it is unlikely that low cytokine levels reflect low
worms numbers, as the majority of mice in the WT vehicle-
treated group harbor the same number of adult worms as seen in
the IL-6 KO vehicle-treated group.
Importantly, our experiments showed that Am80, an
RARα/β agonist, exaggerated the pathology caused by chron-
ic T. muris infection of mice, demonstrated by a crypt hyper-
plasia and CD4+ Tcell infiltrate in this treatment group. This is
surprising, given previous reports showing the beneficial ef-
fects of Am80 in DSS colitis [25], EAE [27] and GvH disease
[39]. Although, we identify IL-6 as a key component of the
mechanism underlying this Am80-driven increase in mucosal
inflammation, the downstream events remains unclear.
Retinoic acid is well-known for its ability to imprint gut
homing on CD4+ T cells via an up-regulation of the gut
homing receptor α4β7 [29], and we also observed this in
MLNs of mice treated with Am80. However, we found this
not to be dependent on the presence of T. muris infection or
IL-6, suggesting that this is also not the mechanism behind the
IL-6 dependent Am80-driven increase in CD4+ T cells in the
colon. The expression of CD4+ T cell chemoattractants in the
gut (CCL3, CCL5, CXCL10, CXCL11, CCL20 and CCL28)
also failed to account for the accumulation of CD4+ T cells in
Am80-treated wild-type mice post T. muris infection, how-
ever, this analysis was carried out on gut tissue from day 35
p.i. which may have been too late to identify chemokines
responsible for recruiting CD4+ T cells into the gut during
the infection period. IL-6 is able to increase leukocyte adhe-
sion via L-selectin [40], and blocking RXR can reduce the
expression of ICAM-1 and VCAM-1 on the endothelium [41].
Therefore it is possible that local changes in adhesion
molecule expressionmay, at least in part, explain the increased
leukocyte presence in the gut following Am80 treatment and
its reduction in the absence of IL-6, although further work is
needed to confirm this.
Despite the established role played by RA in the induction
of Tregs [17] and the role played by IL-6 in driving Th17
development [42], we have no evidence to suggest that the
increased inflammation caused by activation of RAR in WT
mice is due to increased Th17 cell numbers or that the decrease
in inflammation in the absence of IL-6 is due to elevated Treg
numbers. Thus, IL-17 and IL-10 levels in the MLN cells of
WT mice were not significantly changed following Am80-
treatment and intestinal Treg numbers in Am80-treated mice
were also unaltered.
From these findings, we suggest that Am80 promotes IL-6
transcription and production leading to increased gut inflam-
mation. The mouse IL-6 gene is reported to have a putative
RARE binding site [43], however we currently cannot distin-
guish whether the Am80-driven increase in IL-6 in our model
of gut inflammation is due to a direct or indirect effect on the
transcription of this gene. Indeed, previous work has shown
that Am80 treatment can decrease IL-6 production in an
in vivo model of collagen-induced arthritis and in a human
osteosarcoma cell line [15] which may suggest that other
factors are involved in the regulation of IL-6 in our model.
Alternatively, differing concentrations of Am80 or lengths of
treatments may determine the transcriptional regulation of
inflammatory genes, including IL-6. This is supported by a
report which shows that Am80 treatment is beneficial in acute
EAE by inhibiting the induction of Th17 cells, but not in
chronic EAE where a prolonged treatment with Am80 caused
suppression of IL-10 production by T cells [27].
CD4+ T cells are a major producer of IL-6 [44] and we have
shown that administration of Am80 to stimulated CD4+ T cells
can result in the increased production of IL-6 in vitro. Therefore,
Fig. 3 T cells, but not macrophages or epithelial cells, display enhanced
IL-6 production following Am80-treatment in vitro. a Wild-type C57BL/
6 mice were infected with a high dose of T. muris eggs and MLN cells
extracted at day 21 p.i.. 1×106 T cells were stimulated using anti-CD3
(3μg/ml) and anti-CD28 (5μl/well) antibodies, and treated with vehicle,
Am80 (1μM) or Am80 (100 nM) in vitro for 48 h. Similar data was
obtained in an independent experiment sourcing T cells from a low dose
infection. b Bone marrow-derived macrophages were grown from wild-
type C57BL/6 mice and 0.5×106 were stimulated in vitro with T. muris
Excretory-Secretory antigens (E/S) with or without Am80 (1 μM) or
Am80 (100 nM) for 48 h. c The mouse rectal epithelial cell line
CMT93 was grown and 0.5×106 cells were stimulated in vitro with T.
muris Excretory-Secretory antigens (E/S) with or without Am80 (1 μM)
or Am80 (100 nM) for 48 h. Values are means + SEM. The data are
representative of two independent experiments. (n =3–4). *p <0.05,
***p <0.001, ns = no significance
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CD4+ T cells may be the major source of IL-6, controlled
directly or indirectly by the RAR agonist Am80, in our exper-
iments. Furthermore, it has been shown that naive CD4+ Tcells
express RARα, and that TCR stimulation is required for their
response to RA [45]. Therefore, CD4+ Tcells certainly have the
ability to respond to retinoic acid and Am80 during infection
with T. muris . We have also used bone marrow-derived mac-
rophages and the mouse rectal epithelial cell line CMT93 to
show that macrophages and epithelial cells do not respond to
Am80 in vitro to produce elevated levels of IL-6. However,
other investigators have shown that intestinal pig epithelial cells
predominantly produce IL-10 and IL-6 following stimulation
with T. suis E/S, and so these cells may also be responsible for
at least some of the increased IL-6 post Am80-treatment [46].
In conclusion, we show that delivery of the RAR agonist
Am80 during a chronic T. muris infection leads to increased
Th2 responses, but these are insufficient to induce resistance
to the parasite. Further, Am80 treatment leads to an augment-
ed inflammatory response in the gut mucosa demonstrated by
increased CD4+ T cell infiltration and exaggerated crypt hy-
perplasia. We find that these parameters are dependent on IL-
6. These data are in opposition to previous reports where
retinoic acid and activation of both RAR and RXR have been
shown to down-regulate inflammatory processes in both hu-
man ulcerative and murine colitis [18, 21]. Vitamin A supple-
mentation has beenwidely used to lower morbidity in children
and adults harbouring parasitic infections [47]. However, our
findings add caution to the practice of supplementing parasite-
infected individuals with vitamin A, due to the increased
production of the pro-inflammatory cytokine IL-6 following
RAR activation.
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